Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi...

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) T cell therapy use is growing in adult B-cell acute lymphoblastic leukemia (B-ALL).
• Limited prospective trials exist for optimizing CAR T cell therapy administration in this patient population.
• Clinical practice requires evidence-based guidance for effective CAR T cell therapy protocols.

Purpose of the Study:

• To develop and validate consensus recommendations for administering commercially available CAR T cell therapy in adult B-ALL.
• To address critical knowledge gaps in CAR T cell therapy best practices.
• To guide clinical decision-making for CAR T cell therapy in B-ALL.

Main Methods:

• A modified Delphi study was conducted with expert Principal Investigators (PIs) from the ROCCA consortium.
• Consensus was developed through panel meetings and validated by a separate group of PIs.
• Recommendations covered patient selection, treatment setting, toxicity management, and post-therapy monitoring.

Main Results:

• Initially, 58 recommendation statements were evaluated.
• A total of 34 statements achieved consensus among the expert panel after two meetings.
• After validation, 33 consensus recommendation statements were finalized for CAR T cell therapy in adult B-ALL.

Conclusions:

• The study successfully generated 33 consensus recommendations for CAR T cell therapy in adult B-ALL.
• These recommendations provide crucial guidance for optimizing CAR T cell therapy administration.
• The findings aim to enhance clinical practice and improve outcomes for B-ALL patients receiving CAR T cell therapy.